Jane Street
RXRX icon

Jane Street’s Recursion Pharmaceuticals RXRX Stock Holding History

Jane Street’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Sell
682,100
-19,200
-3% -$74.2K ﹤0.01% 4992
2025
Q4 		$2.87M Buy
701,300
+621,800
+782% +$3.08M ﹤0.01% 4120
2025
Q3 		$388K Sell
79,500
-57,400
-42% -$301K ﹤0.01% 8380
2025
Q2 		$693K Sell
136,900
-188,677
-58% -$927K ﹤0.01% 6323
2025
Q1 		$1.72M Buy
325,577
+109,500
+51% +$798K ﹤0.01% 4604
2024
Q4 		$1.46M Buy
216,077
+112,677
+109% +$758K ﹤0.01% 4691
2024
Q3 		$681K Sell
103,400
-27,600
-21% -$198K ﹤0.01% 6634
2024
Q2 		$983K Sell
131,000
-104,400
-44% -$911K ﹤0.01% 5810
2024
Q1 		$2.35M Buy
235,400
+173,200
+278% +$1.93M ﹤0.01% 3844
2023
Q4 		$613K Sell
62,200
-56,300
-48% -$401K ﹤0.01% 6416
2023
Q3 		$907K Buy
118,500
+105,700
+826% +$1.05M ﹤0.01% 5324
2023
Q2 		$95.6K Sell
12,800
-1,300
-9% -$9.1K ﹤0.01% 8019
2023
Q1 		$94K Buy
+14,100
New +$112K ﹤0.01% 8254
2022
Q4 		– Sell
-17,200
Closed -$183K – 10012
2022
Q3 		$183K Buy
+17,200
New +$174K ﹤0.01% 8256

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's RXRX Position: Q1 2026 in Review

Jane Street sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 125,075 shares — an estimated $483K sold.

Jane Street first reported a position in RXRX in Q4 2021 and held it in 15 quarters. The position peaked at $4.31M in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Jane Street reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 125,075 Recursion Pharmaceuticals shares in Q1 2026, an estimated $483K.
  • Jane Street first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • Jane Street's Recursion Pharmaceuticals position peaked at $4.31M in Q2 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.